StreetInsider.com News Articles

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.

H.C. Wainwright 28^thAnnual Global Investment Conference
Presentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ET
Presentation Format: Fireside Chat

A live webcast of the fireside chat will be available on the News

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

H.C. Wainwright 28^thAnnual Global Investment Conference
Presentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ET
Presentation Format: Fireside Chat

A live webcast of the fireside chat will be available on the News

Form 8-K Jasper Therapeutics, For: Aug 21

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26981985.html

Form 8-K Jasper Therapeutics, For: Aug 21

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26981985.html

Form PRE 14A Jasper Therapeutics, For: Aug 24

Mon, 24 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26969262.html

Form PRE 14A Jasper Therapeutics, For: Aug 24

Mon, 24 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26969262.html

H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Tue, 18 Aug 2026 06:45:08 -0400

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $20.00 price target on Jasper Therapeutics (NASDAQ: JSPR).

The analyst commented: "On Friday, Jasper reported 2Q26 earnings and provided its first corporate update since closing the all-stock acquisition of Kira Pharmaceuticals (private) in July. On a fully diluted, as-converted basis, legacy Jasper equity holders own ~6.68% of the combined company, former Kira equity holders ~49.86%, and private placement investors ~43.46%, with ~653.6M shares outstanding. The concurrent $132M PIPE was co-led by reputable life sciences investors, and Mirador Therapeutics (private). Kira separately out-licensed KP-301, a long-acting anti-C5a mAb, and KP-402, a small

Form SCHEDULE 13G Jasper Therapeutics, Filed by: Velan Capital Investment Management LP

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938016.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: Velan Capital Investment Management LP

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938016.html

Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c

Mon, 17 Aug 2026 06:36:36 -0400

Jasper Therapeutics (NASDAQ: JSPR) reported Q2 EPS of ($0.10), $0.18 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Jasper Therapeutics (JSPR) click here.

Form 8-K Jasper Therapeutics, For: Aug 14

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930491.html

Form 8-K Jasper Therapeutics, For: Aug 14

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930491.html

Form 10-Q Jasper Therapeutics, For: Jun 30

Fri, 14 Aug 2026 11:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927004.html

Form 10-Q Jasper Therapeutics, For: Jun 30

Fri, 14 Aug 2026 11:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927004.html

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 11:00:00 -0400

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising $132 million in gross proceeds

REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update.

“We are excited to unite Jasper Therapeutics and

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 11:00:00 -0400

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising $132 million in gross proceeds

“We are excited to unite Jasper Therapeutics and

Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight

Wed, 12 Aug 2026 04:29:01 -0400

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Overweight rating and a price target of $2.00.

The analyst comments: “We are initiating coverage of Jasper Therapeutics (JSPR) with an Overweight rating and a $2 PT, based on lead asset KP-104 in IgAN and C3G. KP-104 simultaneously blocks the alternative pathway (via Factor H modulation) and terminal pathway (via C5 inhibition). While KP-104 has Ph2 PoC efficacy and safety in PNH, it is now advancing into a Ph2 nephrology basket study that initially focuses on IgAN and a smaller C3G cohort (Stage 1) across multiple dosing

Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight

Wed, 12 Aug 2026 04:29:01 -0400

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Overweight rating and a price target of $2.00.

Form D Jasper Therapeutics,

Wed, 05 Aug 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26869297.html

Form D Jasper Therapeutics,

Wed, 05 Aug 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26869297.html

Form 4 Jasper Therapeutics, For: Jul 31 Filed by: Shizuru Judith Anne